Bick, Alexander G.
Popadin, Konstantin
Thorball, Christian W.
Uddin, Md Mesbah
Zanni, Markella V.
Yu, Bing
Cavassini, Matthias
Rauch, Andri
Tarr, Philip
Schmid, Patrick
Bernasconi, Enos
Günthard, Huldrych F.
Libby, Peter
Boerwinkle, Eric
McLaren, Paul J.
Ballantyne, Christie M.
Grinspoon, Steven
Natarajan, Pradeep
Fellay, Jacques
Abela, I.
Aebi-Popp, K.
Anagnostopoulos, A.
Battegay, M.
Bernasconi, E.
Braun, D. L.
Bucher, H. C.
Calmy, A.
Cavassini, M.
Ciuffi, A.
Dollenmaier, G.
Egger, M.
Elzi, L.
Fehr, J.
Fellay, J.
Furrer, H.
Fux, C. A.
Günthard, H. F.
Hachfeld, A.
Haerry, D.
Hasse, B.
Hirsch, H. H.
Hoffmann, M.
Hösli, I.
Huber, M.
Kahlert, C. R.
Kaiser, L.
Keiser, O.
Klimkait, T.
Kouyos, R. D.
Kovari, H.
Kusejko, K.
Martinetti, G.
de Tejada, B. Martinez
Marzolini, C.
Metzner, K. J.
Müller, N.
Nemeth, J.
Nicca, D.
Paioni, P.
Pantaleo, G.
Perreau, M.
Rauch, A.
Schmid, P.
Speck, R.
Stöckle, M.
Tarr, P.
Trkola, A.
Wandeler, G.
Yerly, S.
,
Article History
Received: 18 June 2021
Accepted: 20 December 2021
First Online: 12 January 2022
Change Date: 8 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-022-16151-0
Competing interests
: Dr. Libby is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion, Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Merck, Novartis, Pfizer, Sanofi-Regeneron. Dr. Libby is a member of scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, and XBiotech, Inc. Dr. Libby’s laboratory has received research funding in the last 2 years from Novartis. Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies. Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. Dr Natarajan reported investigator-initiated grants from Amgen, Apple, AstraZeneca, Boston Scientific, and Novartis, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Novartis, Roche / Genentech, and TenSixteen Bio, is a scientific advisory board member of Esperion Therapeutics, geneXwell, and TenSixteen Bio, shareholder of geneXwell and TenSixteen Bio, and spousal employment at Vertex, all unrelated to the present work. None of the authors other than those already mentioned share any competing interests.